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LETTERS TO THE EDITORRegarding “Caution in signing nondisclosure
contracts”
The editorial by K. W. Johnston, “Caution in signing nondis-
closure contracts,” in the June issue of the Journal of Vascular
Surgery (J Vasc Surg 2004;39:1352-1353) deserves more atten-
tion and further emphasis. Dr Johnston rightly touched on the
heart of the problem in the management of data with industrial
partners. Two important issues are apparent: (1) ownership of the
data and (2) freedom of the principle investigator to publish the
data even if the result is negative.
Due to a recent review of the Lifeline Endovascular Registry, I
have first-hand experience in dealing with these 2 issues. According
to the current agreement with industrial partners, the Endovascu-
lar Registry has no ownership of the data it collects and is prohib-
ited from publishing device-specific results. The registry receives
data from manufacturers, and only aggregate results can be re-
ported. This technique of reporting composite data rather than
device-specific results opens the avenue to hide negative results of
certain brands in the registry. With this system, the misconduct by
Guidant would not have been detected because submission of the
data on the Ancure device is from Guidant and not from individual
surgeons. Drug industry–imposed restrictions on publication is
now being addressed by New York’s attorney general in a civil suit
against GlaxoSmithKline alleging that the company committed
fraud by concealing negative information about Paxil, a drug used
to treat depression. A New York Times editorial on the suit said it is
outrageous that any company should have the power to mislead
doctors and their patients by stressing only positive results and
hiding negative findings.1 Obviously, how to report on drug trials
has become a medical journal quandary. The American Medical
Association has called on the government to establish a database or
registry for tracking clinical trials from start to end. A group of 12
medical journals worldwide, including Journal of the American
Medical Association, New England Journal of Medicine, and Lan-
cet, is weighing a proposal that would require a drug trial to be
listed at its start in a public database or registry as a prerequisite to
its results being considered for publication.2 In response to the
public criticism, GlaxoSmithKline plans a public listing of drug
trials on a Web site, which would disclose pre- and post-marketing
data.3 Although details have to be worked out, the idea of a Web
site for public disclosure is certainly a step in the right direction.
What happened in drug trials may certainly be applicable to
device trials. The recent squabble between the Food and Drug
Administration and Medtronic Inc regarding a publication on
endovascular stent graft is a case in point.4 Claiming confidentiality
pertaining to proprietary information and the threat of legal action,
Medtronic Inc has successfully forced the Food and Drug Admin-
istration to withdraw an article entitled “Aneurysm-related mor-
tality rates in the US AneuRx clinical trial,” which had been
accepted for publication in Journal of Vascular Surgery. Clearly,
the issue of proprietary information and whether the public has a
right to see the information companies collect must be addressed
and resolved by the scientific community and regulatory agencies.
The editor of Journal of Vascular Surgery should take note of the
need for openness of data when a report on a device trial is being
reviewed for publication. The Lifeline Board is in the process of
addressing these issues with industrial partners and only time will
tell whether there will be resolution.
Vascular surgeons must actively participate in clinical trials,
but in the process of signing a nondisclosure contract, they are best
advised to follow the recommendations outlined by Johnston. We
must be vigilant of the physician-industry relationship, and free-
dom to publish results by the investigator must be preserved. Inthis changing world, no matter what, there is no substitute for the
dictum of “Patient first.”
James S.T. Yao, MD
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Regarding “Withdrawal of article by the FDA after
objection from Medtronic”
With regard to your recent Special Communication (J Vasc
Surg 2004;40:209-10), we believe it is important that your readers
understand Medtronic’s actions.
Medtronic contested the publishing of a proposed Journal of
Vascular Surgery (JVS) article that referenced our AneuRx device
on 2 grounds. One, the proposed article (written by Food and
Drug Administration [FDA] employees) was inconsistent with the
conclusions of the FDA’s Public Health Notification, dated De-
cember 17, 2003. We contend that having 2 publications from the
FDA that contained different conclusions —could cause confusion
and negatively affect treatment selection and patient care. Two, the
authors of the proposed article did not seek Medtronic’s permis-
sion to use and disclose our confidential and proprietary data
before publication—a practice that is standard in the industry and
required both by the law and the FDA’s own internal guidelines.
Medtronic never questioned the statistics about the AneuRx
device in either the FDA’s December 2003 Public Health Notifi-
cation or the proposed JVS article. Like many leading vascular
surgeons, we questioned the comparison rates for open surgical
repair. Ultimately, the FDA acknowledged Medtronic’s concerns
and asked that the article be withdrawn from publication in JVS, a
fact that has been widely communicated both to the editors of JVS
(through a letter from Dr Daniel Schultz at the FDA) and to the
public in a Wall Street Journal article dated July 9, 2004. The Wall
Street Journal story reported that the FDA withdrew the article
because of concerns about the unauthorized use of Medtronic’s
confidential data, and because “the conclusions drawn in the article
. . .go beyond the information provided in the Public Health
Notification (and) the article does not reflect the FDA’s current
position regarding AneuRx-related mortality.”
Medtronic has released extensive clinical data on the AneuRx
device. Our data have been published in 2 clinical updates issued to
more than 2000 physicians in both 2003 and 2004. In addition, 2
Public Health Notifications have been issued by the FDA on
AneuRx, and 112 peer-reviewed articles have been published on
the performance of this life-saving device over the past 5 years. This
record is unparalleled by peers in our industry.835
